[ad_1]
The Minister of Health, Nelu Tătaru, declared on Wednesday that the first installment of the anti-COVID-19 vaccine would arrive in December, Romania will receive, in this first phase, 1,290,000 doses.
Asked about the interruption in testing of the vaccine produced by AstraZeneca and the University of Oxford, with which the European Commission signed a contract, Tataru said it was a normal situation.
“He is with one of the companies that the European Commission has contracts with. In fact, he is in a phase 3 study. Phase 3 also means patients or subjects with comorbidities and then any incident stops that study, and an independent team evaluates to that patient. ” That is the procedure, it always happens, the 300 million doses bought by the EC, with a possible increase of 100 million, will arrive in December, a first tranche of 30 million, and in the first quarter of the year. future so that we can benefit from them “said Tătaru, on Digi 24, according to News.ro.
Asked if he says that, in fact, the process of acquiring the vaccine goes further, the Minister of Health replied: “The process goes further, there are five companies with which the European Commission is currently in discussions and contracts. It was expected that in December the first section will arrive and in January we will be able to make the first vaccines. The section that came to Romania was 1,290. 000 doses, but as long as this vaccine is safe, we will know it and we will find it on the European market. “
Tataru mentioned that doses were requested from the European Commission for 10,700,000 people.
“Priority will be given to extreme ages, comorbidities, people who work in the health sector, as well as education”, He mentioned.
Final clinical trials for a new coronavirus vaccine developed by AstraZeneca and the University of Oxford were suspended after a participant from the UK had an adverse reaction.
AstraZeneca said it was a “routine” break in case of “unexplained illness.”
Results from clinical trials are closely followed around the world, and the vaccine developed by AstraZeneca and Oxford is considered a strong candidate among those developed globally. After successful test phases 1 and 2, there is hope that it will be one of the first to hit the market.
